FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3037201143> ?p ?o ?g. }

• W3037201143 endingPage "811" @default.
• W3037201143 startingPage "810" @default.
• W3037201143 abstract "To the Editor: Pretibial myxedema (PTM) is a cutaneous manifestation of Graves disease that is often refractory to treatment even with control of underlying thyroid disease. We read with great interest the case series by Hoesly et al1Hoesly P. Tolaymat L. Sluzevich J. Keeling J. Pretibial myxedema successfully treated with intralesional hyaluronidase.JAAD Case Rep. 2018; 4: 874-876Abstract Full Text Full Text PDF PubMed Scopus (5) Google Scholar describing PTM successfully treated with hyaluronidase. Here we report a case of recalcitrant pretibial myxedema that improved significantly with intralesional hyaluronidase and triamcinolone. Our patient is a 43-year-old man who had Graves disease diagnosed after presenting with thyrotoxicosis with hypercalcemic thyrotoxic periodic paralysis necessitating thyroidectomy because of disease severity. Two years after diagnosis, he presented to the dermatology department with an enlarging firm plaque on his right shin (Fig 1) refractory to compression therapy and topical corticosteroids. Also notable on examination was nail clubbing, acropachy, and proptosis with exophthalmos. Incisional biopsy found pools of mucin throughout the reticular dermis consistent with PTM. A mixture of intralesional hyaluronidase (Hylenex, Halozyme Therapeutics, San Diego, CA human recombinant hyaluronidase, 150 U/mL) and triamcinolone were injected into the plaque on the right leg during 5 consecutive office visits at 4-week intervals. For treatment, 1 mL of hyaluronidase (150 U) was mixed with 1 mL of 40 mg/mL triamcinolone at a 1:1 ratio and delivered in 0.05- to 0.1-mL aliquots spaced approximately 1 cm apart. This treatment regimen resulted in a roughly 90% reduction in volume of the plaque with most residual volume at the inferior aspect (Fig 2). Of note, the patient was also taking pentoxifylline, 400 mg 3 times a day, and reported intermittent use of compression stockings during the treatment period. The goal of treatment is a 100% reduction in volume of the plaque with the above regimen and continued use of pentoxifylline and compression therapy.Fig 2Pretibial myxedema. After 5 treatments (20.7 cm long × 13 cm wide × 0.3 cm deep).View Large Image Figure ViewerDownload Hi-res image Download (PPT) Although the precise pathogenesis of PTM is unknown, it is theorized that circulating autoantibodies bind to TSH-Rs on fibroblasts, stimulating T cells to secrete cytokines that promote production of glycosaminoglycans, namely hyaluronic acid and chondroitin sulfate, resulting in excess mucin deposition within the dermis and subcutaneous tissue.2Ai J. Leonhardt J. Heymann W. Autoimmune thyroid diseases: etiology, pathogenesis, and dermatologic manifestations.J Am Acad Dermatol. 2003; 48: 641-662Abstract Full Text Full Text PDF PubMed Scopus (109) Google Scholar PTM classically presents as bilateral, asymmetric, firm, nonpitting, painless nodules and plaques that favor the anterior shins. Conventional therapy includes topical or intralesional corticosteroids and pressure therapy as first line, with oral pentoxifylline as second-line therapy. Intralesional triamcinolone alone has been shown to decrease size and improve appearance of lesions of PTM.3Lan C. Li C. Chen W. Mei X. Zhao J. Hu J. A randomized controlled trial of intralesional glucocorticoid for treating pretibial myxedema.J Clin Med Res. 2015; 7: 862-872Crossref PubMed Google Scholar In the above case, we propose a synergistic effect when used with hyaluronidase. Hyaluronidase is readily available commercially to enhance the dispersion and absorption of subcutaneous drugs and to correct complications related to hyaluronic acid soft tissue augmentation. Treatments are generally well tolerated, with transient burning pain, erythema, and pruritus at the injection site.1Hoesly P. Tolaymat L. Sluzevich J. Keeling J. Pretibial myxedema successfully treated with intralesional hyaluronidase.JAAD Case Rep. 2018; 4: 874-876Abstract Full Text Full Text PDF PubMed Scopus (5) Google Scholar,4Menzinger S. Kaya A. Saurat J. Kaya G. Injected hyaluronidase reduces the volume of exogenous hyaluronate fillers in mice and results in clinical improvement in a patient with pretibial myxedema.Dermatopathology. 2016; 3: 61-67Crossref PubMed Google Scholar,5Sorenson E. Shive M. Holland V. Chuang G. Intralesional hyaluronidase for the treatment of pretibial myxedema.J Am Acad Dermatol. 2018; 79: AB170Abstract Full Text Full Text PDF Google Scholar Pretibial myxedema successfully treated with intralesional hyaluronidaseJAAD Case ReportsVol. 4Issue 9PreviewPretibial myxedema (PTM) is a rare form of diffuse dermal mucinosis caused by glycosaminoglycan deposition in pretibial skin. It generally occurs in association with autoimmune thyroid disorders and affects 0.5% to 4.3% of patients with Graves disease (GD).1 PTM rarely improves with correction of the hyperthyroid state and may lead to pain, pruritus, or cosmetic concerns.2 Therefore, treatment is usually desired. Topical and intralesional corticosteroids, octreotide, and systemic immunomodulating agents have been used with largely unsatisfactory results. Full-Text PDF Open Access" @default.
• W3037201143 created "2020-07-02" @default.
• W3037201143 creator A5007450062 @default.
• W3037201143 creator A5019512590 @default.
• W3037201143 creator A5061068660 @default.
• W3037201143 creator A5086966175 @default.
• W3037201143 date "2020-09-01" @default.
• W3037201143 modified "2023-10-15" @default.
• W3037201143 title "Pretibial myxedema treated with intralesional hyaluronidase and triamcinolone" @default.
• W3037201143 cites W2014119246 @default.
• W3037201143 cites W2104529098 @default.
• W3037201143 cites W2467949190 @default.
• W3037201143 cites W2894895498 @default.
• W3037201143 cites W4231168770 @default.
• W3037201143 doi "https://doi.org/10.1016/j.jdcr.2020.06.021" @default.
• W3037201143 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7452363" @default.
• W3037201143 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32885009" @default.
• W3037201143 hasPublicationYear "2020" @default.
• W3037201143 type Work @default.
• W3037201143 sameAs 3037201143 @default.
• W3037201143 citedByCount "2" @default.
• W3037201143 countsByYear W30372011432021 @default.
• W3037201143 countsByYear W30372011432022 @default.
• W3037201143 crossrefType "journal-article" @default.
• W3037201143 hasAuthorship W3037201143A5007450062 @default.
• W3037201143 hasAuthorship W3037201143A5019512590 @default.
• W3037201143 hasAuthorship W3037201143A5061068660 @default.
• W3037201143 hasAuthorship W3037201143A5086966175 @default.
• W3037201143 hasBestOaLocation W30372011431 @default.
• W3037201143 hasConcept C126322002 @default.
• W3037201143 hasConcept C141071460 @default.
• W3037201143 hasConcept C16005928 @default.
• W3037201143 hasConcept C181199279 @default.
• W3037201143 hasConcept C185592680 @default.
• W3037201143 hasConcept C2775847430 @default.
• W3037201143 hasConcept C2776652619 @default.
• W3037201143 hasConcept C2778903070 @default.
• W3037201143 hasConcept C2780101021 @default.
• W3037201143 hasConcept C2780375986 @default.
• W3037201143 hasConcept C526584372 @default.
• W3037201143 hasConcept C55493867 @default.
• W3037201143 hasConcept C71924100 @default.
• W3037201143 hasConceptScore W3037201143C126322002 @default.
• W3037201143 hasConceptScore W3037201143C141071460 @default.
• W3037201143 hasConceptScore W3037201143C16005928 @default.
• W3037201143 hasConceptScore W3037201143C181199279 @default.
• W3037201143 hasConceptScore W3037201143C185592680 @default.
• W3037201143 hasConceptScore W3037201143C2775847430 @default.
• W3037201143 hasConceptScore W3037201143C2776652619 @default.
• W3037201143 hasConceptScore W3037201143C2778903070 @default.
• W3037201143 hasConceptScore W3037201143C2780101021 @default.
• W3037201143 hasConceptScore W3037201143C2780375986 @default.
• W3037201143 hasConceptScore W3037201143C526584372 @default.
• W3037201143 hasConceptScore W3037201143C55493867 @default.
• W3037201143 hasConceptScore W3037201143C71924100 @default.
• W3037201143 hasIssue "9" @default.
• W3037201143 hasLocation W30372011431 @default.
• W3037201143 hasLocation W30372011432 @default.
• W3037201143 hasLocation W30372011433 @default.
• W3037201143 hasLocation W30372011434 @default.
• W3037201143 hasOpenAccess W3037201143 @default.
• W3037201143 hasPrimaryLocation W30372011431 @default.
• W3037201143 hasRelatedWork W1968472829 @default.
• W3037201143 hasRelatedWork W1978672871 @default.
• W3037201143 hasRelatedWork W2005121843 @default.
• W3037201143 hasRelatedWork W2073548357 @default.
• W3037201143 hasRelatedWork W2157088832 @default.
• W3037201143 hasRelatedWork W2268299562 @default.
• W3037201143 hasRelatedWork W2397327971 @default.
• W3037201143 hasRelatedWork W2518542439 @default.
• W3037201143 hasRelatedWork W3004958447 @default.
• W3037201143 hasRelatedWork W3037201143 @default.
• W3037201143 hasVolume "6" @default.
• W3037201143 isParatext "false" @default.
• W3037201143 isRetracted "false" @default.
• W3037201143 magId "3037201143" @default.
• W3037201143 workType "article" @default.